Go Pro
→ Not oil. Not solar. Bigger. (From Behind the Markets) (Ad)tc pixel Free ATYR Stock Alerts

aTyr Pharma (ATYR) Financials

aTyr Pharma logo
$0.49 -0.02 (-4.59%)
Closing price 04:00 PM Eastern
Extended Trading
$0.49 +0.00 (+0.33%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for aTyr Pharma

Annual Income Statements for aTyr Pharma

This table shows aTyr Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -48 -58 -48 -35 -23 -16 -34 -45 -50 -64 -74
Consolidated Net Income / (Loss)		 -48 -58 -48 -35 -24 -16 -34 -45 -50 -64 -74
Net Income / (Loss) Continuing Operations		 -48 -58 -47 -35 -23 -16 -34 -46 -50 -64 -74
Total Pre-Tax Income 		-48 -58 -47 -35 -23 -16 -34 -46 -50 -64 -74
Total Operating Income		 -48 -58 -47 -33 -23 -16 -34 -46 -55 -68 -78
Total Gross Profit		 0.00 0.00 0.00 0.00 0.42 10 0.00 10 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.42 10 0.00 10 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 48 58 47 33 23 26 34 57 55 68 78
Selling, General & Admin Expense		 13 15 17 12 9.35 9.08 11 14 13 14 18
Research & Development Expense		 35 43 30 20 14 17 23 43 42 54 60
Total Other Income / (Expense), net		 -0.36 0.04 0.00 -1.70 0.00 -0.32 0.00 0.00 4.52 3.89 3.50
Other Income / (Expense), net		 -0.36 0.07 - -1.70 - -0.32 - - 4.52 3.89 3.50
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 0.00 -0.16 -0.01 -0.01 -0.01 -0.01 0.00 -0.01
Basic Earnings per Share		 ($3.03) ($2.44) ($26.13) ($16.11) ($7.03) ($1.77) ($1.77) ($1.60) ($0.94) ($0.86) ($0.80)
Weighted Average Basic Shares Outstanding		 15.84M 23.68M 1.85M 2.14M 3.36M 9.16M 19.08M 28.42M 53.61M 74.26M 92.99M
Diluted Earnings per Share		 ($3.03) ($2.44) ($26.13) ($16.11) ($7.03) ($1.77) ($1.77) ($1.60) ($0.94) ($0.86) ($0.80)
Weighted Average Diluted Shares Outstanding		 15.84M 23.68M 1.85M 2.14M 3.36M 9.16M 19.08M 28.42M 53.61M 74.26M 92.99M
Weighted Average Basic & Diluted Shares Outstanding		 15.84M 23.68M 1.85M 2.14M 3.36M 9.16M 19.08M 53.16M 67.75M 88.86M 98.05M

Quarterly Income Statements for aTyr Pharma

This table shows aTyr Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -15 -15 -16 -17 -15 -15 -20 -26 -14 -11
Consolidated Net Income / (Loss)		 -11 -15 -15 -16 -17 -15 -15 -20 -26 -14 -11
Net Income / (Loss) Continuing Operations		 -13 -13 -15 -16 -17 -19 -15 -20 -26 -14 -11
Total Pre-Tax Income 		-13 -13 -15 -16 -17 -19 -15 -20 -26 -14 -11
Total Operating Income		 -13 -16 -17 -17 -18 -16 -16 -20 -27 -15 -11
Total Gross Profit		 0.35 -0.35 0.24 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.35 -0.35 0.24 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 13 16 17 17 18 16 16 20 27 15 11
Selling, General & Admin Expense		 2.65 3.20 3.51 3.34 3.34 3.59 3.96 4.93 4.81 3.91 4.12
Research & Development Expense		 10 13 13 14 15 12 12 15 22 11 7.32
Total Other Income / (Expense), net		 0.00 2.47 1.15 1.01 0.88 -3.04 0.89 0.78 1.00 0.83 0.64
Other Income / (Expense), net		 - - 1.15 1.01 0.88 - 0.89 0.78 1.00 0.83 0.64
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.00 -0.00 0.00 0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.20) ($0.23) ($0.23) ($0.23) ($0.23) ($0.17) ($0.17) ($0.22) ($0.26) ($0.15) ($0.11)
Weighted Average Basic Shares Outstanding		 57.89M 53.61M 66.08M 72.28M 75.80M 74.26M 86.49M 90.12M 97.15M 92.99M 98.04M
Diluted Earnings per Share		 ($0.20) ($0.23) ($0.23) ($0.23) ($0.23) ($0.17) ($0.17) ($0.22) ($0.26) ($0.15) ($0.11)
Weighted Average Diluted Shares Outstanding		 57.89M 53.61M 66.08M 72.28M 75.80M 74.26M 86.49M 90.12M 97.15M 92.99M 98.04M
Weighted Average Basic & Diluted Shares Outstanding		 58.56M 67.75M 69.01M 75.80M 83.94M 88.86M 89.00M 97.99M 97.99M 98.05M 98.05M

Annual Cash Flow Statements for aTyr Pharma

This table details how cash moves in and out of aTyr Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 39 -15 -17 1.87 -14 7.74 -15 11 13 -12 -1.03
Net Cash From Operating Activities		 -37 -53 -42 -31 -20 -15 -33 -42 -33 -69 -62
Net Cash From Continuing Operating Activities		 -37 -53 -42 -31 -20 -15 -33 -42 -33 -69 -62
Net Income / (Loss) Continuing Operations		 -48 -58 -48 -35 -24 -16 -34 -45 -50 -64 -74
Consolidated Net Income / (Loss)		 -48 -58 -48 -35 -24 -16 -34 -45 -50 -64 -74
Depreciation Expense		 0.87 0.90 0.71 0.75 0.64 0.57 0.48 0.23 0.59 0.71 0.66
Amortization Expense		 0.79 0.53 0.01 -0.26 0.45 0.81 1.20 2.00 -1.02 -1.87 -0.97
Non-Cash Adjustments To Reconcile Net Income		 6.54 5.23 7.37 4.42 2.46 1.81 1.62 2.06 2.59 2.99 4.99
Changes in Operating Assets and Liabilities, net		 2.98 -1.67 -2.26 -1.45 0.21 -2.26 -2.59 -0.83 15 -6.92 7.45
Net Cash From Investing Activities		 -72 34 -28 37 4.93 6.90 -92 47 -20 17 -5.05
Net Cash From Continuing Investing Activities		 -72 34 -28 37 4.93 6.90 -92 47 -20 17 -5.05
Purchase of Property, Plant & Equipment		 -0.66 -0.60 -1.31 -0.59 -0.08 -0.20 -0.19 -1.64 -4.22 -0.07 -0.08
Purchase of Investments		 -109 -28 -78 -40 -41 -21 -127 -42 -107 -69 -93
Sale of Property, Plant & Equipment		 - - 0.00 0.00 0.05 0.02 0.05 0.18 0.02 0.01 0.01
Sale and/or Maturity of Investments		 38 62 51 78 46 28 35 91 91 86 88
Net Cash From Financing Activities		 148 4.70 53 -4.24 1.34 16 110 5.45 66 40 66
Net Cash From Continuing Financing Activities		 148 4.70 53 -4.24 1.34 16 110 5.45 66 40 66
Repayment of Debt		 -5.24 -5.20 0.00 -4.67 -8.00 -9.08 0.00 0.00 0.00 0.00 0.00
Issuance of Common Equity		 78 0.16 43 0.43 9.34 25 110 5.52 67 40 67
Other Financing Activities, net		 - - - - - 0.00 0.00 -0.07 -0.39 -0.50 -0.54
Cash Interest Paid		 0.93 0.23 1.00 1.70 1.12 0.31 0.00 0.05 0.17 0.14 0.09

Quarterly Cash Flow Statements for aTyr Pharma

This table details how cash moves in and out of aTyr Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.49 13 -16 -0.32 4.68 -0.38 -1.21 7.30 -11 4.12 -1.17
Net Cash From Operating Activities		 -9.56 -11 -22 -20 -13 -13 -15 -14 -20 -12 -13
Net Cash From Continuing Operating Activities		 -9.56 -11 -22 -20 -13 -13 -15 -14 -20 -12 -13
Net Income / (Loss) Continuing Operations		 -11 -15 -15 -16 -17 -15 -15 -20 -26 -14 -11
Consolidated Net Income / (Loss)		 -11 -15 -15 -16 -17 -15 -15 -20 -26 -14 -11
Depreciation Expense		 0.18 0.18 0.18 0.18 0.18 0.18 0.17 0.17 0.17 0.17 0.16
Amortization Expense		 -0.16 -0.66 -0.22 -0.53 -0.40 -0.73 -0.31 -0.24 -0.29 -0.13 -0.02
Non-Cash Adjustments To Reconcile Net Income		 0.66 0.67 0.74 0.73 0.75 0.77 1.18 1.31 1.31 1.20 1.31
Changes in Operating Assets and Liabilities, net		 1.10 3.52 -7.59 -4.52 3.57 1.62 -1.58 4.40 4.09 0.54 -3.17
Net Cash From Investing Activities		 4.38 18 -1.36 6.73 18 -6.09 -4.42 3.30 -20 16 11
Net Cash From Continuing Investing Activities		 4.38 18 -1.36 6.73 18 -6.09 -4.42 3.30 -20 16 11
Purchase of Property, Plant & Equipment		 -0.56 -0.02 -0.02 -0.01 -0.02 -0.03 0.00 -0.01 -0.04 -0.03 -0.14
Purchase of Investments		 -29 -9.67 -21 -19 -2.91 -26 -23 -18 -39 -13 -5.87
Sale and/or Maturity of Investments		 34 28 20 26 21 20 19 21 19 29 18
Net Cash From Financing Activities		 2.68 6.03 7.73 13 -0.11 19 19 18 30 -0.13 -0.14
Net Cash From Continuing Financing Activities		 2.68 6.03 7.73 13 -0.11 19 19 18 30 -0.13 -0.14
Issuance of Common Equity		 2.79 6.15 7.85 14 0.02 19 19 18 30 0.01 0.00
Other Financing Activities, net		 -0.11 -0.12 -0.12 -0.12 -0.13 -0.13 -0.13 -0.13 -0.14 -0.14 -0.14
Cash Interest Paid		 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.02 0.02 0.02

Annual Balance Sheets for aTyr Pharma

This table presents aTyr Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 130 81 89 53 36 39 116 96 121 97 93
Total Current Assets		 98 75 87 51 32 36 114 81 103 82 80
Cash & Equivalents		 53 38 21 23 9.21 17 2.34 9.98 23 11 11
Short-Term Investments		 43 34 64 27 22 15 106 56 76 61 68
Accounts Receivable		 - - - - 0.10 2.04 0.44 12 2.44 1.74 0.87
Prepaid Expenses		 2.42 2.62 1.87 1.26 0.68 1.80 5.22 2.95 2.39 8.09 0.68
Plant, Property, & Equipment, net		 1.79 1.42 2.28 1.85 1.27 0.90 0.54 3.06 5.53 4.85 4.26
Total Noncurrent Assets		 30 4.34 0.09 0.09 2.99 2.30 1.43 12 12 10 8.50
Noncurrent Note & Lease Receivables		 - - - - - - 0.00 1.25 1.79 1.19 0.60
Other Noncurrent Operating Assets		 0.12 0.33 0.09 0.09 2.99 2.30 1.43 11 10 8.83 7.91
Total Liabilities & Shareholders' Equity		 130 81 89 53 36 39 116 96 121 97 93
Total Liabilities		 15 18 25 19 15 7.24 6.41 25 30 27 26
Total Current Liabilities		 12 8.53 10 11 13 5.86 6.01 14 16 15 15
Accounts Payable		 3.87 2.61 2.28 1.04 0.85 1.43 1.03 3.11 3.53 4.32 3.89
Accrued Expenses		 4.60 5.45 3.10 2.03 2.38 3.57 4.00 9.86 12 9.39 9.79
Other Current Liabilities		 - - - 0.00 0.96 0.86 0.98 0.89 1.33 1.25 1.47
Total Noncurrent Liabilities		 2.48 9.20 15 8.26 2.24 1.38 0.40 11 14 12 11
Capital Lease Obligations		 - - - - - - - 1.01 1.43 0.89 0.26
Other Noncurrent Operating Liabilities		 0.57 - - 0.00 2.24 1.38 0.40 9.63 12 11 10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 115 63 64 34 21 31 109 71 90 70 67
Total Preferred & Common Equity		 115 63 64 34 21 32 109 71 91 70 67
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 115 63 64 34 21 32 109 71 91 70 67
Common Stock		 273 279 329 332 344 370 482 490 559 602 674
Retained Earnings		 -158 -216 -264 -299 -322 -339 -372 -418 -468 -532 -606
Accumulated Other Comprehensive Income / (Loss)		 -0.17 -0.08 -0.12 -0.06 -0.04 -0.04 -0.26 -0.43 -0.07 -0.04 -0.01
Noncontrolling Interest		 - - - 0.00 -0.16 -0.17 -0.18 -0.18 -0.19 -0.19 -0.19

Quarterly Balance Sheets for aTyr Pharma

This table presents aTyr Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 125 113 106 92 97 102 107 80
Total Current Assets		 107 97 90 76 83 87 93 68
Cash & Equivalents		 9.79 6.81 6.81 11 10 17 6.15 10
Short-Term Investments		 92 78 72 55 66 63 84 57
Accounts Receivable		 2.09 2.48 1.63 1.83 0.99 0.50 1.04 0.48
Prepaid Expenses		 3.08 9.94 10 8.50 5.93 6.65 1.77 0.59
Plant, Property, & Equipment, net		 5.64 5.35 5.18 5.02 4.68 4.53 4.43 4.24
Total Noncurrent Assets		 12 11 10 10 9.29 9.52 9.21 7.84
Noncurrent Note & Lease Receivables		 1.79 1.64 1.49 1.34 1.04 0.89 0.75 0.45
Other Noncurrent Operating Assets		 10 9.34 8.97 8.94 8.25 8.62 8.46 7.39
Total Liabilities & Shareholders' Equity		 125 113 106 92 97 102 107 80
Total Liabilities		 27 29 25 26 22 27 27 22
Total Current Liabilities		 13 16 12 14 11 16 16 12
Accounts Payable		 2.04 4.89 1.26 3.95 1.53 3.88 4.06 2.76
Accrued Expenses		 9.61 9.95 9.41 8.96 7.86 10 10 7.46
Other Current Liabilities		 1.23 1.14 1.17 1.21 1.29 1.33 1.43 1.49
Total Noncurrent Liabilities		 14 13 13 12 12 11 11 10
Capital Lease Obligations		 1.44 1.30 1.16 1.03 0.75 0.60 0.40 0.15
Other Noncurrent Operating Liabilities		 13 12 12 11 11 11 11 10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 98 84 81 65 75 75 80 58
Total Preferred & Common Equity		 98 84 82 65 75 75 80 58
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 98 84 82 65 75 75 80 58
Common Stock		 552 568 582 582 622 641 672 675
Retained Earnings		 -453 -484 -500 -517 -547 -566 -592 -617
Accumulated Other Comprehensive Income / (Loss)		 -0.29 -0.16 -0.17 0.04 -0.07 -0.08 -0.00 -0.07
Noncontrolling Interest		 -0.19 -0.18 -0.18 -0.19 -0.19 -0.19 -0.19 -0.19

Annual Metrics And Ratios for aTyr Pharma

This table displays calculated financial ratios and metrics derived from aTyr Pharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 23,648,404.00 23,718,529.00 29,758,347.00 30,023,543.00 3,890,185.00 10,124,027.00 27,790,677.00 29,009,382.00 58,560,061.00 - 97,986,634.00
DEI Adjusted Shares Outstanding		 23,648,404.00 23,718,529.00 29,758,347.00 30,023,543.00 3,890,185.00 10,124,027.00 27,790,677.00 29,009,382.00 58,560,061.00 - 97,986,634.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.03 -2.44 -1.62 -1.15 -6.03 -1.60 -1.22 -1.56 -0.86 - -0.76
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 2,377.49% -100.00% 0.00% -100.00% -33.43% 0.00%
EBITDA Growth		 -108.44% -21.87% 17.76% 26.69% 35.66% 32.16% -117.75% -36.58% -15.06% -24.81% -14.17%
EBIT Growth		 -103.98% -20.64% 18.54% 26.79% 33.43% 29.37% -109.58% -36.42% -8.60% -23.66% -15.78%
NOPAT Growth		 -102.16% -21.68% 18.63% 30.39% 29.99% 30.76% -113.78% -36.42% -18.35% -23.66% -14.30%
Net Income Growth		 -97.01% -20.60% 16.68% 28.40% 31.62% 31.24% -108.11% -34.23% -11.16% -27.06% -15.78%
EPS Growth		 89.79% 19.47% 16.68% 28.40% 56.36% 74.82% 0.00% 9.60% 41.25% 8.51% 6.98%
Operating Cash Flow Growth		 -61.22% -43.66% 19.86% 26.68% 35.57% 23.54% -116.16% -26.64% 20.69% -108.06% 10.32%
Free Cash Flow Firm Growth		 -87.77% -43.79% 14.88% 32.01% 39.93% 15.48% -104.90% -48.28% 30.42% -101.31% 14.88%
Invested Capital Growth		 -432.75% 26.10% 70.01% 111.81% -1,122.96% 85.16% 692.68% 405.76% -202.00% 77.57% -692.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 51.80% 22.34% -100.00% 0.00% -100.00% 299.15% 0.00%
EBITDA Q/Q Growth		 -30.65% 0.00% 0.00% 8.56% 2.71% 4.45% -11.97% 3.53% -11.99% 0.11% 6.43%
EBIT Q/Q Growth		 -29.09% 0.00% 0.00% 9.31% 0.00% 4.15% -12.21% 1.47% -7.43% 0.20% 5.76%
NOPAT Q/Q Growth		 -28.13% 0.00% 0.00% 13.76% 0.00% 6.04% -12.21% 1.47% -17.07% 0.20% 1.30%
Net Income Q/Q Growth		 -27.87% 0.00% 0.00% 12.99% 1.46% 32.00% -43.44% 2.26% -16.77% -0.33% 1.34%
EPS Q/Q Growth		 82.74% 0.00% 0.00% 12.99% -12.84% 0.00% -6.63% -3.90% 3.09% 6.52% 2.44%
Operating Cash Flow Q/Q Growth		 -12.31% -3.65% 3.17% 14.97% -0.39% -3.27% -8.84% -5.76% -2.13% -3.09% 1.49%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -0.39% 0.23% -11.84% -16.44% 13.51% -4.16% 1.13%
Invested Capital Q/Q Growth		 -201.76% 0.00% 0.00% -83.77% -86.12% 18.97% 11.98% 2,358.00% -151.63% -881.11% -14.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00% 100.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -5,188.63% -142.08% 0.00% -425.34% 0.00% -29,395.32% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -5,445.02% -152.19% 0.00% -446.79% 0.00% -28,899.57% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -5,445.02% -155.24% 0.00% -446.79% 0.00% -28,899.57% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -5,593.13% -155.24% 0.00% -436.53% 0.00% -27,243.83% 0.00%
Tax Burden Percent		 100.00% 99.92% 102.25% 100.00% 102.72% 100.00% 99.30% 97.70% 100.00% 94.27% 100.00%
Interest Burden Percent		 100.00% 100.05% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -882.68% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -867.83% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 832.42% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -80.18% -65.06% -75.89% -70.51% -86.34% -61.82% -48.04% -50.26% -62.31% -79.88% -108.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -17,964.44% 0.00% 0.00% -2,076.58% -1,016.65% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -51.67% -43.33% 0.00% -43.92% 0.00% -62.45% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -53.08% -43.33% 0.00% -42.91% 0.00% -58.88% 0.00%
Return on Common Equity (ROCE)		 -16.11% -65.06% -75.89% -70.51% -86.58% -62.20% -48.16% -50.36% -62.45% -80.06% -108.41%
Return on Equity Simple (ROE_SIMPLE)		 -41.70% -92.12% -75.04% -102.57% -111.41% -51.28% -30.90% -63.44% 0.00% -91.44% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -41 -33 -23 -16 -11 -24 -32 -38 -48 -54
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,811.52% -106.53% 0.00% -312.76% 0.00% -20,229.70% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -23.28% -18.52% -23.04% -23.34% -26.89% -18.83% -14.28% -14.86% -14.77% -19.63% -26.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -44.93% -41.83% -67.22% -80.45%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 2,216.11% 86.80% 0.00% 134.62% 0.00% 5,862.55% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 3,328.91% 165.39% 0.00% 412.17% 0.00% 23,137.02% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 5,545.02% 252.19% 0.00% 546.79% 0.00% 28,999.57% 0.00%
Earnings before Interest and Taxes (EBIT)		 -48 -58 -47 -35 -23 -16 -34 -46 -50 -68 -74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -46 -56 -46 -34 -22 -15 -32 -44 -51 -69 -74
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 28.29 11.37 22.70 6.19 0.77 1.24 1.90 0.89 0.91 4.34 1.14
Price to Tangible Book Value (P/TBV)		 28.29 11.37 22.70 6.19 0.77 1.24 1.90 0.89 0.91 4.34 1.14
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 38.44 3.76 0.00 6.12 0.00 1,293.07 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 1,295.14 0.00 0.00 81.90 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.71 0.00 0.00 0.00 989.13 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.15 0.31 0.48 0.42 0.00 0.00 0.01 0.02 0.01 0.00
Long-Term Debt to Equity		 0.02 0.15 0.23 0.25 0.00 0.00 0.00 0.01 0.02 0.01 0.00
Financial Leverage		 -1.05 -1.05 -1.04 -1.01 -1.02 -1.03 -0.99 -0.96 -1.00 -1.05 -1.09
Leverage Ratio		 1.26 1.18 1.34 1.45 1.63 1.43 1.10 1.17 1.34 1.36 1.38
Compound Leverage Factor		 1.26 1.18 1.34 1.45 1.63 1.43 1.10 1.17 1.34 1.36 1.38
Debt to Total Capital		 4.28% 13.18% 23.50% 32.27% 29.36% 0.00% 0.00% 1.39% 1.55% 1.25% 0.38%
Short-Term Debt to Total Capital		 2.80% 0.47% 5.97% 15.63% 29.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.48% 12.72% 17.53% 16.63% 0.00% 0.00% 0.00% 1.39% 1.55% 1.25% 0.38%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% -0.54% -0.53% -0.16% -0.25% -0.20% -0.26% -0.28%
Common Equity to Total Capital		 95.72% 86.82% 76.50% 67.73% 71.18% 100.53% 100.16% 98.86% 98.65% 99.01% 99.90%
Debt to EBITDA		 -0.11 -0.17 -0.43 -0.47 -0.40 0.00 0.00 -0.02 -0.03 -0.01 0.00
Net Debt to EBITDA		 2.60 1.18 1.41 0.98 1.02 0.00 0.00 1.47 1.90 1.03 1.05
Long-Term Debt to EBITDA		 -0.04 -0.16 -0.32 -0.24 0.00 0.00 0.00 -0.02 -0.03 -0.01 0.00
Debt to NOPAT		 -0.15 -0.24 -0.60 -0.70 -0.54 0.00 0.00 -0.03 -0.04 -0.02 0.00
Net Debt to NOPAT		 3.61 1.64 1.98 1.46 1.39 0.00 0.00 2.01 2.52 1.50 1.44
Long-Term Debt to NOPAT		 -0.05 -0.23 -0.45 -0.36 0.00 0.00 0.00 -0.03 -0.04 -0.02 0.00
Altman Z-Score		 131.38 19.03 29.99 -2.63 -13.28 -9.18 15.06 -5.20 -4.31 -2.42 -9.12
Noncontrolling Interest Sharing Ratio		 79.91% 0.00% 0.00% 0.00% -0.29% -0.62% -0.24% -0.20% -0.23% -0.23% -0.28%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.06 8.77 8.37 4.69 2.47 6.06 18.89 5.83 6.27 5.48 5.30
Quick Ratio		 7.86 8.46 8.19 4.57 2.42 5.75 18.02 5.62 6.13 4.93 5.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -42 -36 -24 -15 -12 -25 -37 -26 -52 -45
Operating Cash Flow to CapEx		 -5,541.72% -8,810.17% -3,228.96% -5,229.46% -71,475.00% -8,315.76% -23,292.25% -2,864.98% -790.98% -119,170.69% -95,363.08%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,444.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -1,822.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -1,843.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.28 0.00 0.10 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 9.78 0.00 1.70 0.00 0.11 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.27 9.64 0.00 5.77 0.00 0.05 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 37.34 0.00 214.55 0.00 3,239.96 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 37.34 0.00 214.55 0.00 3,239.96 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.16 -3.81 -1.14 0.14 -1.38 -0.21 1.22 6.15 -6.27 -1.41 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.68 -13.18 0.00 2.82 0.00 -0.06 0.00
Increase / (Decrease) in Invested Capital		 -4.19 1.35 2.67 1.28 -1.52 1.18 1.42 4.93 -12 4.86 -9.73
Enterprise Value (EV)		 3,134 647 1,393 175 -6.34 7.43 100 -1.79 -14 232 -1.89
Market Capitalization		 3,254 714 1,458 208 16 39 208 64 83 304 77
Book Value per Share		 $4.87 $2.65 $2.16 $1.12 $5.45 $3.13 $3.93 $2.46 $1.55 $0.83 $0.69
Tangible Book Value per Share		 $4.87 $2.65 $2.16 $1.12 $5.45 $3.13 $3.93 $2.46 $1.55 $0.83 $0.69
Total Capital		 120 72 84 50 30 31 109 72 92 71 68
Total Debt		 5.14 9.54 20 16 8.74 0.00 0.00 1.01 1.43 0.89 0.26
Total Long-Term Debt		 1.78 9.20 15 8.26 0.00 0.00 0.00 1.01 1.43 0.89 0.26
Net Debt		 -120 -67 -65 -34 -22 -32 -108 -65 -97 -71 -78
Capital Expenditures (CapEx)		 0.66 0.60 1.31 0.59 0.03 0.18 0.14 1.46 4.20 0.06 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.37 -5.57 -3.51 -1.81 -3.41 -2.02 -0.36 0.86 -12 -5.14 -14
Debt-free Net Working Capital (DFNWC)		 89 67 82 48 28 30 108 67 87 67 65
Net Working Capital (NWC)		 86 66 77 40 19 30 108 67 87 67 65
Net Nonoperating Expense (NNE)		 15 17 15 12 7.52 5.09 9.97 13 12 16 20
Net Nonoperating Obligations (NNO)		 -120 -67 -65 -34 -22 -32 -108 -65 -97 -71 -78
Total Depreciation and Amortization (D&A)		 1.66 1.43 0.73 0.49 1.08 1.38 1.67 2.23 -0.43 -1.17 -0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -806.87% -19.34% 0.00% 8.31% 0.00% -2,186.38% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 6,573.22% 283.76% 0.00% 645.19% 0.00% 28,505.11% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 4,502.84% 283.76% 0.00% 645.19% 0.00% 28,505.11% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.03) ($2.44) ($1.87) ($1.15) ($7.03) ($1.77) ($1.77) ($1.60) ($0.94) ($0.86) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding		 23.68M 23.75M 29.80M 34.77M 9.35M 16.01M 27.80M 28.42M 53.61M 74.26M 92.99M
Adjusted Diluted Earnings per Share		 ($3.03) ($2.44) ($1.87) ($1.15) ($7.03) ($1.77) ($1.77) ($1.60) ($0.94) ($0.86) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding		 23.68M 23.75M 29.80M 34.77M 9.35M 16.01M 27.80M 28.42M 53.61M 74.26M 92.99M
Adjusted Basic & Diluted Earnings per Share		 ($3.03) ($2.44) ($1.87) ($1.15) ($7.03) ($1.77) ($1.77) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 15.84M 23.68M 25.80M 29.96M 3.36M 9.16M 19.08M 53.16M 67.75M 88.86M 98.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -41 -33 -23 -16 -11 -24 -32 -38 -48 -54
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,811.52% -106.53% 0.00% -312.76% 0.00% -20,229.70% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -5,445.02% -155.24% 0.00% -446.79% 0.00% -28,899.57% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,995.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -1,398.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -2,016.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -1,419.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for aTyr Pharma

This table displays calculated financial ratios and metrics derived from aTyr Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 57,046,172.00 58,560,061.00 67,750,024.00 69,010,940.00 75,796,198.00 - 88,858,612.00 89,004,436.00 97,986,634.00 97,986,634.00 98,051,212.00
DEI Adjusted Shares Outstanding		 57,046,172.00 58,560,061.00 67,750,024.00 69,010,940.00 75,796,198.00 - 88,858,612.00 89,004,436.00 97,986,634.00 97,986,634.00 98,051,212.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.20 -0.25 -0.23 -0.24 -0.23 - -0.17 -0.22 -0.26 -0.14 -0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -103.40% 0.00% 0.00% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 6.71% -153.78% -33.68% -31.81% -38.76% 0.45% 3.27% -17.68% -47.98% 10.23% 29.08%
EBIT Growth		 4.76% -100.74% -29.58% -32.12% -36.83% 0.87% 3.91% -19.78% -49.16% 6.71% 27.48%
NOPAT Growth		 6.50% -100.74% -30.10% -27.71% -43.82% 0.87% 5.19% -17.31% -47.41% 6.47% 27.50%
Net Income Growth		 14.37% -96.32% -29.58% -32.12% -52.19% -1.46% 3.91% -19.78% -49.16% 6.71% 27.48%
EPS Growth		 56.52% 11.54% 20.69% -4.55% -15.00% 26.09% 26.09% 4.35% -13.04% 11.76% 35.29%
Operating Cash Flow Growth		 22.16% -6.68% -3,693.22% -70.27% -37.65% -18.71% 31.10% 32.06% -55.62% 7.13% 18.83%
Free Cash Flow Firm Growth		 29.27% 111.83% -158.66% -67.54% -152.42% -1,383.40% 41.82% 70.84% 42.87% 96.09% 98.65%
Invested Capital Growth		 -1,096.40% -202.00% 134.74% 508.96% 107.23% 77.57% -168.33% -223.92% -5,522.22% -692.32% -1,065.00%
Revenue Q/Q Growth		 0.00% -200.00% 0.00% -100.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.31% -30.53% 5.58% -7.28% -4.95% 6.36% 3.21% -30.50% -31.96% 46.15% 23.53%
EBIT Q/Q Growth		 -2.21% -26.51% 2.96% -5.29% -5.86% 8.35% 0.58% -31.25% -31.81% 45.76% 22.72%
NOPAT Q/Q Growth		 6.96% -26.51% -4.24% -4.08% -4.78% 12.80% 0.30% -28.78% -31.66% 44.68% 22.71%
Net Income Q/Q Growth		 8.10% -30.14% -4.98% -5.29% -5.86% 13.28% 0.58% -31.25% -31.81% 45.76% 22.72%
EPS Q/Q Growth		 9.09% -15.00% 0.00% 0.00% 0.00% 26.09% 0.00% -29.41% -18.18% 42.31% 26.67%
Operating Cash Flow Q/Q Growth		 20.41% -15.72% -102.31% 8.63% 35.65% 0.20% -17.42% 9.90% -47.37% 40.44% -2.63%
Free Cash Flow Firm Q/Q Growth		 40.79% 120.39% -1,376.09% -8.74% 10.79% -3.68% 42.16% 45.49% -74.75% 92.90% 80.07%
Invested Capital Q/Q Growth		 -148.11% -151.63% 117.28% 279.13% -95.62% -881.11% 47.37% -587.57% -91.82% -14.14% 22.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -3,569.12% 0.00% -6,607.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -3,573.65% 0.00% -7,079.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -3,573.65% 0.00% -6,590.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -3,213.03% 0.00% -6,590.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 89.91% 109.44% 100.00% 100.00% 100.00% 79.37% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 84.52% 100.00% 100.00% 100.00% 119.22% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -49.27% -62.31% -55.60% 0.00% -78.13% -79.88% -79.70% -85.40% -103.49% -108.11% -105.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -4,186.30% -1,190.39% -27,948.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -347.11% 0.00% -30.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -312.09% 0.00% -30.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -49.37% -62.45% -55.70% 0.00% -78.31% -80.06% -79.88% -85.60% -103.76% -108.41% -105.93%
Return on Equity Simple (ROE_SIMPLE)		 -43.87% 0.00% -63.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.83 -11 -12 -12 -13 -11 -11 -14 -19 -10 -8.01
NOPAT Margin		 -2,501.56% 0.00% -4,955.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.83% -4.44% -3.92% -4.54% -5.51% -4.64% -4.84% -6.77% -9.08% -4.82% -3.93%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.16% -13.61% -14.68% -19.19% -15.66% -14.60% -18.89% -23.27% -15.33% -13.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 750.42% 0.00% 1,492.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 2,923.23% 0.00% 5,686.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 3,673.65% 0.00% 7,179.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -16 -15 -16 -17 -16 -15 -20 -26 -14 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -16 -16 -17 -17 -16 -15 -20 -26 -14 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.92 0.91 1.56 1.32 2.04 4.34 3.58 6.03 0.88 1.14 1.32
Price to Tangible Book Value (P/TBV)		 0.92 0.91 1.56 1.32 2.04 4.34 3.58 6.03 0.88 1.14 1.32
Price to Revenue (P/Rev)		 8.39 0.00 224.68 183.09 567.67 1,293.07 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 45.00 7.34 379.20 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 82.87 51.28 290.45 989.13 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.00
Long-Term Debt to Equity		 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.00
Financial Leverage		 -1.01 -1.00 -1.01 -0.98 -1.01 -1.05 -1.00 -1.01 -1.07 -1.09 -1.07
Leverage Ratio		 1.26 1.34 1.29 1.27 1.33 1.36 1.32 1.33 1.37 1.38 1.33
Compound Leverage Factor		 1.26 1.13 1.29 1.27 1.33 1.62 1.32 1.33 1.37 1.38 1.33
Debt to Total Capital		 1.44% 1.55% 1.52% 1.41% 1.55% 1.25% 0.99% 0.80% 0.49% 0.38% 0.26%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.44% 1.55% 1.52% 1.41% 1.55% 1.25% 0.99% 0.80% 0.49% 0.38% 0.26%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.19% -0.20% -0.22% -0.22% -0.28% -0.26% -0.25% -0.25% -0.24% -0.28% -0.33%
Common Equity to Total Capital		 98.75% 98.65% 98.70% 98.81% 98.73% 99.01% 99.26% 99.45% 99.74% 99.90% 100.07%
Debt to EBITDA		 -0.03 -0.03 -0.02 -0.02 -0.01 -0.01 -0.01 -0.01 -0.01 0.00 0.00
Net Debt to EBITDA		 2.22 1.90 1.40 1.22 0.94 1.03 1.17 1.12 1.13 1.05 0.95
Long-Term Debt to EBITDA		 -0.03 -0.03 -0.02 -0.02 -0.01 -0.01 -0.01 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 -0.04 -0.04 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 -0.01 0.00 0.00
Net Debt to NOPAT		 3.07 2.52 2.02 1.77 1.36 1.50 1.61 1.63 1.63 1.44 1.29
Long-Term Debt to NOPAT		 -0.04 -0.04 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 -0.01 0.00 0.00
Altman Z-Score		 -2.40 -3.36 -2.83 -3.58 -4.68 -0.65 -0.29 2.48 -6.11 -6.99 -8.35
Noncontrolling Interest Sharing Ratio		 -0.21% -0.23% -0.19% 0.00% -0.23% -0.23% -0.23% -0.24% -0.26% -0.28% -0.29%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.33 6.27 6.07 7.63 5.41 5.48 7.79 5.63 5.93 5.30 5.78
Quick Ratio		 8.09 6.13 5.44 6.77 4.80 4.93 7.24 5.21 5.82 5.25 5.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.09 1.24 -16 -17 -15 -16 -9.22 -5.03 -8.78 -0.62 -0.12
Operating Cash Flow to CapEx		 -1,716.16% -65,070.59% -131,647.06% -255,612.50% -87,720.00% -72,955.56% 0.00% -154,377.78% -55,340.54% -39,341.94% -9,070.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 7.26 0.00 0.29 0.40 0.12 0.11 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.10 0.00 0.11 0.11 0.04 0.05 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 50.30 0.00 1,272.84 904.74 3,042.70 3,239.96 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 50.30 0.00 1,272.84 904.74 3,042.70 3,239.96 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.49 -6.27 1.08 4.11 0.18 -1.41 -0.74 -5.09 -9.76 -11 -8.62
Invested Capital Turnover		 -9.58 0.00 -0.58 0.38 -0.20 -0.06 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.74 -12 4.20 5.11 2.67 4.86 -1.82 -9.19 -9.94 -9.73 -7.88
Enterprise Value (EV)		 -11 -14 49 30 68 232 193 371 -19 -1.89 9.92
Market Capitalization		 90 83 132 108 133 304 268 451 71 77 76
Book Value per Share		 $1.72 $1.55 $1.25 $1.18 $0.86 $0.83 $0.84 $0.84 $0.82 $0.69 $0.59
Tangible Book Value per Share		 $1.72 $1.55 $1.25 $1.18 $0.86 $0.83 $0.84 $0.84 $0.82 $0.69 $0.59
Total Capital		 100 92 86 83 66 71 76 75 80 68 58
Total Debt		 1.44 1.43 1.30 1.16 1.03 0.89 0.75 0.60 0.40 0.26 0.15
Total Long-Term Debt		 1.44 1.43 1.30 1.16 1.03 0.89 0.75 0.60 0.40 0.26 0.15
Net Debt		 -101 -97 -83 -77 -65 -71 -76 -80 -90 -78 -66
Capital Expenditures (CapEx)		 0.56 0.02 0.02 0.01 0.02 0.02 0.00 0.01 0.04 0.03 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.71 -12 -3.56 -0.02 -3.79 -5.14 -3.76 -8.39 -13 -14 -11
Debt-free Net Working Capital (DFNWC)		 94 87 81 78 62 67 73 72 77 65 56
Net Working Capital (NWC)		 94 87 81 78 62 67 73 72 77 65 56
Net Nonoperating Expense (NNE)		 2.51 3.59 3.84 4.19 4.56 3.90 3.84 5.31 7.02 3.61 2.79
Net Nonoperating Obligations (NNO)		 -101 -97 -83 -77 -65 -71 -76 -80 -90 -78 -66
Total Depreciation and Amortization (D&A)		 0.02 -0.49 -0.04 -0.35 -0.22 -0.55 -0.14 -0.07 -0.12 0.03 0.14
Debt-free, Cash-free Net Working Capital to Revenue		 -71.83% 0.00% -605.27% -3.74% -1,611.91% -2,186.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 879.20% 0.00% 13,764.80% 13,343.54% 26,467.66% 28,505.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 879.20% 0.00% 13,764.80% 13,343.54% 26,467.66% 28,505.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.23) ($0.23) ($0.23) ($0.23) ($0.17) ($0.17) ($0.22) ($0.26) ($0.15) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 57.89M 53.61M 66.08M 72.28M 75.80M 74.26M 86.49M 90.12M 97.15M 92.99M 98.04M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.23) ($0.23) ($0.23) ($0.23) ($0.17) ($0.17) ($0.22) ($0.26) ($0.15) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 57.89M 53.61M 66.08M 72.28M 75.80M 74.26M 86.49M 90.12M 97.15M 92.99M 98.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.56M 67.75M 69.01M 75.80M 83.94M 88.86M 89.00M 97.99M 97.99M 98.05M 98.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.83 -11 -12 -12 -13 -11 -11 -14 -19 -10 -8.01
Normalized NOPAT Margin		 -2,501.56% 0.00% -4,955.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -3,573.65% 0.00% -6,590.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

aTyr Pharma’s latest quarter shows a company with a strong cash position, but continuing heavy operating losses and ongoing shareholder dilution. For a pre-revenue biotech name like ATYR, the balance sheet and cash burn rate matter more than traditional revenue growth, and this quarter’s numbers suggest the company still has runway, though it is spending aggressively on research and development.

  • Liquidity improved sharply. As of Q1 2026, aTyr reported $66.5 million in cash and short-term investments, up from $57.1 million at the end of Q4 2025 and above the $54.6 million level seen in Q3 2025.
  • Working capital remains solid. Current assets of $67.6 million exceeded current liabilities of $11.7 million, giving the company a comfortable near-term liquidity cushion.
  • Operating cash burn improved year over year. Net cash used in operating activities was $12.5 million in Q1 2026, better than $15.4 million in Q1 2025 and $20.5 million in Q2 2025.
  • Net loss narrowed sequentially. Q1 2026 net loss was $10.8 million, an improvement from $14.0 million in Q4 2025.
  • R&D spending remains elevated, which is a positive if it is supporting late-stage pipeline progress. Research and development expense was $7.3 million in Q1 2026, still a major investment in the company’s core development efforts.
  • Revenue is still essentially absent. The company reported $0 in revenue in Q1 2026, so valuation continues to depend on clinical and regulatory execution rather than sales growth.
  • Other income helped offset losses. aTyr generated $644,000 of other income in Q1 2026, which provided some support to pre-tax results but is not a durable operating driver.
  • Share count remains high. Weighted average diluted shares outstanding were about 98.0 million in Q1 2026, so per-share recovery will likely remain difficult without meaningful clinical success or profitability.
  • Losses are still substantial. The company posted an operating loss of $11.4 million in Q1 2026 and a net loss of $10.8 million, showing the business is still far from breakeven.
  • Equity financing has been a recurring source of cash. In prior quarters, especially Q3 2025 and Q2 2025, aTyr raised significant capital through common stock issuance, signaling ongoing dilution risk for existing shareholders.

Bottom line: aTyr Pharma appears well-capitalized for the near term, and its latest quarter shows some improvement in cash use and net losses. However, the company is still burning cash, has no revenue, and depends on outside financing and pipeline progress to create shareholder value. For retail investors, the stock remains a high-risk biotech story where clinical milestones will matter much more than quarterly earnings.

07/21/26 12:09 AM ETAI Generated. May Contain Errors.

aTyr Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, aTyr Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

aTyr Pharma's net income appears to be on an upward trend, with a most recent value of -$74.12 million in 2025, rising from -$47.97 million in 2015. The previous period was -$64.02 million in 2024. See aTyr Pharma's forecast for analyst expectations on what's next for the company.

aTyr Pharma's total operating income in 2025 was -$77.63 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $77.82 million

Over the last 10 years, aTyr Pharma's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

aTyr Pharma's total liabilities were at $25.72 million at the end of 2025, a 4.8% decrease from 2024, and a 75.8% increase since 2015.

In the past 10 years, aTyr Pharma's cash and equivalents has ranged from $2.34 million in 2021 to $53.03 million in 2015, and is currently $10.74 million as of their latest financial filing in 2025.

Over the last 10 years, aTyr Pharma's book value per share changed from 4.87 in 2015 to 0.69 in 2025, a change of -85.8%.


Related Companies

Financial statements for NASDAQ:ATYR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Sam Altman backs small company that could save U.S. power grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
It’s one of Trump’s biggest holdings. Do you own it?
President Trump holds up to $5 million in shares of an AI company that just landed a nearly $10 billion Pentag...
InvestorPlace | Sponsoredtc pixel